Japanese clear Novartis' Gilenya, Vertex's hep C drug

Japanese regulators approved two important new drugs: Novartis's Gilenya, the first oral multiple sclerosis treatment, and Vertex Pharmaceuticals's Telavic, the hepatitis C treatment sold as Incivek in the U.S. and developed for Japan in partnership with Mitsubishi Tanabe Pharma. Novartis release | Release

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.